Wegovy (semaglutide) is similar to Ozempic, a well-known diabetes medication, but Wegovy is specifically approved for weight loss and weight management
To be clear and despite the labeling the product doesn't contain any of the clinically tested, FDA-approved pharmaceutical properties that enable GLP-1 medications to mimic the effects of a hormone called glucagon-like peptide 1, which the body produces after food consumption, thus sending a signal to the brain that the stomach feels full
Retatrutide works on three receptors (GLP-1, GIP, and glucagon), while Semaglutide targets only GLP-1 and Tirzepatide targets two (GLP-1 and GIP)
After quality control and curation, a total of 56 plasma metabolites were retained for downstream statistical analysis
Currently, the use of GSH as a therapeutic agent is limited by its unfavourable biochemical and pharmacokinetic properties